| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-HIV Agents | 193 | 2025 | 836 | 26.510 |
Why?
|
| Pre-Exposure Prophylaxis | 125 | 2025 | 227 | 21.150 |
Why?
|
| HIV Infections | 220 | 2025 | 2945 | 16.660 |
Why?
|
| Tenofovir | 117 | 2025 | 274 | 14.840 |
Why?
|
| Emtricitabine | 84 | 2025 | 204 | 11.700 |
Why?
|
| Adenine | 73 | 2025 | 301 | 10.020 |
Why?
|
| Organophosphates | 52 | 2025 | 155 | 7.100 |
Why?
|
| Medication Adherence | 77 | 2025 | 505 | 6.700 |
Why?
|
| Alcoholic Beverages | 10 | 2023 | 30 | 4.400 |
Why?
|
| Alcohol Drinking | 26 | 2023 | 816 | 4.340 |
Why?
|
| Dried Blood Spot Testing | 32 | 2025 | 121 | 3.950 |
Why?
|
| Transgender Persons | 37 | 2025 | 187 | 3.760 |
Why?
|
| Homosexuality, Male | 44 | 2024 | 193 | 3.720 |
Why?
|
| Beer | 6 | 2023 | 12 | 3.160 |
Why?
|
| Lamivudine | 15 | 2025 | 65 | 2.870 |
Why?
|
| Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 13 | 2025 | 19 | 2.850 |
Why?
|
| Organophosphonates | 14 | 2015 | 99 | 2.620 |
Why?
|
| Leukocytes, Mononuclear | 27 | 2025 | 571 | 2.530 |
Why?
|
| Zidovudine | 14 | 2012 | 79 | 2.460 |
Why?
|
| HIV-1 | 28 | 2025 | 886 | 2.430 |
Why?
|
| Sexual and Gender Minorities | 18 | 2024 | 229 | 2.360 |
Why?
|
| Alcoholism | 16 | 2022 | 818 | 2.360 |
Why?
|
| Tandem Mass Spectrometry | 25 | 2025 | 556 | 2.330 |
Why?
|
| Humans | 365 | 2025 | 138972 | 2.210 |
Why?
|
| Primary Health Care | 21 | 2023 | 1776 | 2.200 |
Why?
|
| Adult | 182 | 2025 | 38393 | 2.050 |
Why?
|
| Consumer Behavior | 4 | 2021 | 73 | 1.990 |
Why?
|
| Disease Transmission, Infectious | 10 | 2018 | 68 | 1.990 |
Why?
|
| Deoxycytidine | 8 | 2015 | 192 | 1.980 |
Why?
|
| Female | 238 | 2025 | 74016 | 1.970 |
Why?
|
| Male | 226 | 2025 | 68250 | 1.920 |
Why?
|
| Young Adult | 105 | 2025 | 13371 | 1.900 |
Why?
|
| Chromatography, Liquid | 20 | 2025 | 449 | 1.900 |
Why?
|
| Antiviral Agents | 15 | 2024 | 733 | 1.840 |
Why?
|
| HIV Protease Inhibitors | 14 | 2016 | 68 | 1.840 |
Why?
|
| Oligopeptides | 10 | 2015 | 266 | 1.800 |
Why?
|
| Anti-Retroviral Agents | 14 | 2023 | 244 | 1.600 |
Why?
|
| Hair | 10 | 2024 | 88 | 1.570 |
Why?
|
| Deoxyadenine Nucleotides | 3 | 2016 | 16 | 1.540 |
Why?
|
| Deoxycytosine Nucleotides | 3 | 2016 | 13 | 1.530 |
Why?
|
| Thymine Nucleotides | 6 | 2016 | 19 | 1.490 |
Why?
|
| Middle Aged | 112 | 2025 | 33782 | 1.450 |
Why?
|
| Pyridines | 8 | 2024 | 494 | 1.450 |
Why?
|
| Atazanavir Sulfate | 9 | 2016 | 44 | 1.400 |
Why?
|
| Ethanol | 7 | 2023 | 615 | 1.340 |
Why?
|
| Prospective Studies | 54 | 2025 | 7661 | 1.340 |
Why?
|
| Adolescent | 100 | 2025 | 21581 | 1.310 |
Why?
|
| Blood Chemical Analysis | 11 | 2019 | 110 | 1.280 |
Why?
|
| HIV Seropositivity | 9 | 2023 | 126 | 1.230 |
Why?
|
| Commerce | 5 | 2022 | 80 | 1.220 |
Why?
|
| Health Policy | 5 | 2018 | 398 | 1.220 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 3 | 2015 | 29 | 1.200 |
Why?
|
| Reverse Transcriptase Inhibitors | 15 | 2023 | 85 | 1.170 |
Why?
|
| Food Industry | 2 | 2020 | 16 | 1.160 |
Why?
|
| Alanine | 12 | 2025 | 152 | 1.130 |
Why?
|
| Cytidine Triphosphate | 6 | 2023 | 18 | 1.120 |
Why?
|
| Erythrocytes | 7 | 2025 | 701 | 1.110 |
Why?
|
| Viral Load | 17 | 2025 | 495 | 1.100 |
Why?
|
| Polyphosphates | 7 | 2024 | 43 | 1.070 |
Why?
|
| Cytochrome P-450 CYP3A | 5 | 2012 | 89 | 1.050 |
Why?
|
| Coinfection | 7 | 2025 | 137 | 1.050 |
Why?
|
| Alcohol-Related Disorders | 4 | 2016 | 125 | 1.050 |
Why?
|
| Drug Monitoring | 6 | 2025 | 209 | 1.040 |
Why?
|
| HIV | 13 | 2023 | 246 | 1.030 |
Why?
|
| Public Policy | 3 | 2022 | 82 | 1.030 |
Why?
|
| Chemoprevention | 7 | 2018 | 93 | 0.980 |
Why?
|
| Wine | 2 | 2023 | 12 | 0.980 |
Why?
|
| Micrognathism | 2 | 2016 | 18 | 0.970 |
Why?
|
| Osteogenesis, Distraction | 2 | 2016 | 18 | 0.960 |
Why?
|
| Sarcoma, Ewing | 4 | 2023 | 100 | 0.950 |
Why?
|
| South Africa | 18 | 2025 | 229 | 0.900 |
Why?
|
| Interrupted Time Series Analysis | 6 | 2022 | 74 | 0.900 |
Why?
|
| Drug Resistance, Viral | 7 | 2025 | 118 | 0.880 |
Why?
|
| Cross-Over Studies | 10 | 2024 | 555 | 0.870 |
Why?
|
| Phosphorous Acids | 3 | 2024 | 15 | 0.830 |
Why?
|
| Substance-Related Disorders | 5 | 2023 | 1085 | 0.830 |
Why?
|
| Drug Interactions | 18 | 2025 | 404 | 0.820 |
Why?
|
| Community Participation | 2 | 2023 | 133 | 0.810 |
Why?
|
| Hyperthermia, Induced | 3 | 2015 | 120 | 0.810 |
Why?
|
| Pharmacogenetics | 4 | 2024 | 164 | 0.800 |
Why?
|
| Harm Reduction | 2 | 2016 | 39 | 0.800 |
Why?
|
| Circulating Tumor DNA | 1 | 2023 | 32 | 0.790 |
Why?
|
| Health Personnel | 3 | 2022 | 734 | 0.780 |
Why?
|
| Delivery of Health Care | 7 | 2023 | 963 | 0.770 |
Why?
|
| Dideoxynucleotides | 7 | 2023 | 16 | 0.740 |
Why?
|
| Rectum | 4 | 2024 | 188 | 0.740 |
Why?
|
| Directly Observed Therapy | 3 | 2022 | 17 | 0.730 |
Why?
|
| Health Services | 1 | 2022 | 116 | 0.730 |
Why?
|
| Forgiveness | 1 | 2021 | 1 | 0.710 |
Why?
|
| Cephalometry | 2 | 2020 | 33 | 0.710 |
Why?
|
| Sustained Virologic Response | 3 | 2025 | 42 | 0.710 |
Why?
|
| Indinavir | 5 | 2006 | 7 | 0.710 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2023 | 232 | 0.700 |
Why?
|
| Latin America | 6 | 2023 | 90 | 0.700 |
Why?
|
| Mexico | 10 | 2023 | 232 | 0.700 |
Why?
|
| Depression | 8 | 2022 | 1470 | 0.690 |
Why?
|
| Ritonavir | 6 | 2012 | 75 | 0.690 |
Why?
|
| Social Norms | 2 | 2018 | 30 | 0.670 |
Why?
|
| Product Labeling | 1 | 2020 | 10 | 0.660 |
Why?
|
| Acrocephalosyndactylia | 5 | 2024 | 12 | 0.660 |
Why?
|
| Hormones | 2 | 2022 | 141 | 0.660 |
Why?
|
| Psychotherapy, Brief | 3 | 2016 | 38 | 0.660 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 80 | 0.660 |
Why?
|
| Contraceptive Devices, Female | 4 | 2025 | 11 | 0.660 |
Why?
|
| Kenya | 11 | 2025 | 122 | 0.660 |
Why?
|
| Internet | 6 | 2017 | 674 | 0.660 |
Why?
|
| Drug Administration Schedule | 12 | 2021 | 769 | 0.650 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2020 | 115 | 0.640 |
Why?
|
| Alcoholic Intoxication | 3 | 2021 | 70 | 0.640 |
Why?
|
| Administration, Oral | 15 | 2025 | 787 | 0.630 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 3 | 2015 | 6 | 0.630 |
Why?
|
| Postpartum Period | 6 | 2024 | 346 | 0.630 |
Why?
|
| Preventive Health Services | 2 | 2018 | 153 | 0.620 |
Why?
|
| Referral and Consultation | 6 | 2023 | 795 | 0.610 |
Why?
|
| Pyridones | 6 | 2022 | 170 | 0.610 |
Why?
|
| Head | 1 | 2020 | 115 | 0.610 |
Why?
|
| Viremia | 8 | 2024 | 149 | 0.600 |
Why?
|
| Biological Assay | 2 | 2018 | 129 | 0.600 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 3 | 0.590 |
Why?
|
| Europe | 10 | 2025 | 407 | 0.580 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2018 | 26 | 0.580 |
Why?
|
| Kidney Function Tests | 3 | 2018 | 156 | 0.580 |
Why?
|
| Dextromethorphan | 1 | 2018 | 21 | 0.580 |
Why?
|
| Sexual Behavior | 9 | 2024 | 488 | 0.580 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2018 | 31 | 0.580 |
Why?
|
| Pharmacogenomic Variants | 1 | 2018 | 33 | 0.570 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2020 | 286 | 0.570 |
Why?
|
| European Union | 2 | 2017 | 12 | 0.570 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2022 | 611 | 0.560 |
Why?
|
| Solid Phase Extraction | 3 | 2014 | 25 | 0.550 |
Why?
|
| Iohexol | 2 | 2015 | 22 | 0.550 |
Why?
|
| Review Literature as Topic | 1 | 2018 | 74 | 0.550 |
Why?
|
| Scotland | 3 | 2022 | 18 | 0.540 |
Why?
|
| Nucleosides | 4 | 2022 | 26 | 0.540 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 88 | 0.540 |
Why?
|
| General Practitioners | 2 | 2014 | 26 | 0.540 |
Why?
|
| Training Support | 1 | 2017 | 37 | 0.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 1742 | 0.530 |
Why?
|
| Sexually Transmitted Diseases | 4 | 2024 | 163 | 0.530 |
Why?
|
| Reimbursement, Incentive | 1 | 2017 | 41 | 0.520 |
Why?
|
| United Kingdom | 5 | 2021 | 321 | 0.520 |
Why?
|
| Peru | 7 | 2023 | 61 | 0.520 |
Why?
|
| Glomerular Filtration Rate | 5 | 2018 | 741 | 0.520 |
Why?
|
| Mandible | 2 | 2020 | 68 | 0.520 |
Why?
|
| Health Care Costs | 2 | 2018 | 419 | 0.520 |
Why?
|
| Diketopiperazines | 5 | 2022 | 15 | 0.520 |
Why?
|
| Brain Concussion | 6 | 2025 | 576 | 0.510 |
Why?
|
| Deoxyguanine Nucleotides | 1 | 2016 | 12 | 0.510 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 103 | 0.510 |
Why?
|
| Genitalia | 1 | 2016 | 33 | 0.510 |
Why?
|
| Hepatitis B virus | 5 | 2024 | 34 | 0.500 |
Why?
|
| Desiccation | 2 | 2014 | 22 | 0.500 |
Why?
|
| Dermatitis, Atopic | 3 | 2025 | 331 | 0.500 |
Why?
|
| Sofosbuvir | 5 | 2022 | 59 | 0.490 |
Why?
|
| Pierre Robin Syndrome | 1 | 2016 | 9 | 0.490 |
Why?
|
| Diphosphates | 5 | 2021 | 19 | 0.490 |
Why?
|
| Raltegravir Potassium | 2 | 2015 | 19 | 0.490 |
Why?
|
| Child | 36 | 2025 | 21936 | 0.490 |
Why?
|
| Quality of Life | 9 | 2025 | 2962 | 0.490 |
Why?
|
| Tobacco Products | 1 | 2017 | 131 | 0.470 |
Why?
|
| Cost of Illness | 4 | 2025 | 309 | 0.470 |
Why?
|
| Bone Neoplasms | 3 | 2023 | 248 | 0.470 |
Why?
|
| Craniofacial Abnormalities | 1 | 2016 | 74 | 0.470 |
Why?
|
| Reproducibility of Results | 15 | 2023 | 3313 | 0.460 |
Why?
|
| Genitalia, Female | 1 | 2015 | 41 | 0.460 |
Why?
|
| Sexual Partners | 6 | 2024 | 188 | 0.450 |
Why?
|
| Pregnancy | 16 | 2024 | 6870 | 0.450 |
Why?
|
| Self Report | 11 | 2024 | 842 | 0.450 |
Why?
|
| Specimen Handling | 2 | 2014 | 182 | 0.440 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2015 | 281 | 0.440 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2015 | 62 | 0.440 |
Why?
|
| Condoms | 4 | 2021 | 102 | 0.440 |
Why?
|
| Cefoxitin | 1 | 2014 | 7 | 0.430 |
Why?
|
| Bone Density | 5 | 2020 | 489 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2023 | 1058 | 0.420 |
Why?
|
| Lopinavir | 2 | 2013 | 31 | 0.410 |
Why?
|
| Pyrimidines | 3 | 2025 | 472 | 0.410 |
Why?
|
| Post-Concussion Syndrome | 4 | 2024 | 178 | 0.410 |
Why?
|
| Text Messaging | 5 | 2022 | 163 | 0.410 |
Why?
|
| Colombia | 6 | 2023 | 41 | 0.410 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 242 | 0.400 |
Why?
|
| Peripartum Period | 2 | 2024 | 22 | 0.400 |
Why?
|
| Half-Life | 7 | 2016 | 146 | 0.400 |
Why?
|
| Patient Compliance | 9 | 2017 | 602 | 0.400 |
Why?
|
| Netherlands | 7 | 2024 | 87 | 0.390 |
Why?
|
| Aged | 27 | 2025 | 24172 | 0.390 |
Why?
|
| Immunologic Factors | 1 | 2015 | 243 | 0.390 |
Why?
|
| Biomarkers | 8 | 2023 | 4095 | 0.380 |
Why?
|
| Child, Preschool | 24 | 2025 | 11158 | 0.380 |
Why?
|
| HIV Seronegativity | 3 | 2010 | 30 | 0.380 |
Why?
|
| Sex Factors | 11 | 2024 | 2050 | 0.380 |
Why?
|
| Cisplatin | 2 | 2013 | 327 | 0.370 |
Why?
|
| Attitude of Health Personnel | 3 | 2017 | 1159 | 0.370 |
Why?
|
| Treatment Outcome | 21 | 2021 | 10921 | 0.370 |
Why?
|
| Social Support | 4 | 2024 | 628 | 0.370 |
Why?
|
| Spodoptera | 3 | 2024 | 40 | 0.370 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2014 | 201 | 0.370 |
Why?
|
| Healthy Volunteers | 5 | 2019 | 208 | 0.370 |
Why?
|
| Cross-Sectional Studies | 13 | 2025 | 5530 | 0.360 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2024 | 2138 | 0.360 |
Why?
|
| Phosphates | 2 | 2015 | 180 | 0.350 |
Why?
|
| Unsafe Sex | 4 | 2021 | 63 | 0.350 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2025 | 416 | 0.350 |
Why?
|
| Wales | 2 | 2021 | 24 | 0.350 |
Why?
|
| Ribavirin | 4 | 2018 | 82 | 0.350 |
Why?
|
| Infant, Extremely Premature | 2 | 2023 | 66 | 0.350 |
Why?
|
| Hepatitis B | 4 | 2024 | 68 | 0.340 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 1148 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2021 | 1377 | 0.340 |
Why?
|
| Microsomes, Liver | 1 | 2010 | 81 | 0.340 |
Why?
|
| HIV Integrase Inhibitors | 2 | 2021 | 69 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 1811 | 0.330 |
Why?
|
| Diabetic Nephropathies | 1 | 2014 | 299 | 0.330 |
Why?
|
| Follow-Up Studies | 14 | 2024 | 5152 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 2 | 2011 | 97 | 0.330 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2024 | 348 | 0.330 |
Why?
|
| Risk-Taking | 5 | 2019 | 345 | 0.320 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 1235 | 0.320 |
Why?
|
| Feeding Behavior | 1 | 2016 | 685 | 0.320 |
Why?
|
| Neuropsychological Tests | 4 | 2025 | 1057 | 0.320 |
Why?
|
| Longitudinal Studies | 10 | 2023 | 2850 | 0.320 |
Why?
|
| Inflammation | 3 | 2022 | 2853 | 0.320 |
Why?
|
| Multidrug Resistance-Associated Proteins | 4 | 2024 | 35 | 0.320 |
Why?
|
| Hepatitis C | 4 | 2022 | 247 | 0.320 |
Why?
|
| Drug Stability | 7 | 2014 | 164 | 0.320 |
Why?
|
| Cerebral Palsy | 2 | 2022 | 113 | 0.310 |
Why?
|
| Carcinoma, Small Cell | 1 | 2010 | 171 | 0.310 |
Why?
|
| RNA, Viral | 9 | 2023 | 684 | 0.310 |
Why?
|
| Macaca | 4 | 2023 | 64 | 0.310 |
Why?
|
| Counseling | 4 | 2021 | 392 | 0.310 |
Why?
|
| Zimbabwe | 6 | 2025 | 59 | 0.310 |
Why?
|
| Liver Neoplasms | 3 | 2021 | 719 | 0.310 |
Why?
|
| Receptors, Odorant | 2 | 2021 | 32 | 0.310 |
Why?
|
| Family Characteristics | 2 | 2021 | 192 | 0.310 |
Why?
|
| Mobile Applications | 2 | 2022 | 178 | 0.310 |
Why?
|
| Pilot Projects | 7 | 2024 | 1765 | 0.300 |
Why?
|
| Nucleotides | 3 | 2016 | 128 | 0.300 |
Why?
|
| Feasibility Studies | 11 | 2025 | 980 | 0.300 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2014 | 357 | 0.300 |
Why?
|
| Hypothermia, Induced | 1 | 2010 | 90 | 0.300 |
Why?
|
| Retrospective Studies | 14 | 2023 | 15901 | 0.300 |
Why?
|
| Public Health | 3 | 2023 | 582 | 0.300 |
Why?
|
| Telemedicine | 3 | 2024 | 876 | 0.300 |
Why?
|
| England | 2 | 2021 | 102 | 0.300 |
Why?
|
| Central Nervous System Stimulants | 2 | 2022 | 176 | 0.290 |
Why?
|
| Clinical Trials as Topic | 6 | 2019 | 1034 | 0.290 |
Why?
|
| Airway Obstruction | 3 | 2016 | 164 | 0.290 |
Why?
|
| Brazil | 7 | 2023 | 166 | 0.290 |
Why?
|
| Genotype | 9 | 2024 | 1849 | 0.290 |
Why?
|
| CD4 Lymphocyte Count | 6 | 2015 | 280 | 0.290 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2025 | 590 | 0.280 |
Why?
|
| Drug Therapy, Combination | 12 | 2019 | 1031 | 0.280 |
Why?
|
| Administration, Rectal | 2 | 2024 | 13 | 0.280 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2017 | 2047 | 0.280 |
Why?
|
| Metabolic Clearance Rate | 4 | 2018 | 116 | 0.280 |
Why?
|
| Body Fluids | 5 | 2019 | 70 | 0.270 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2017 | 10 | 0.270 |
Why?
|
| Mental Health Services | 2 | 2025 | 434 | 0.270 |
Why?
|
| Moths | 2 | 2024 | 44 | 0.270 |
Why?
|
| United States | 20 | 2025 | 15074 | 0.270 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2025 | 185 | 0.270 |
Why?
|
| Efficiency | 2 | 2025 | 100 | 0.270 |
Why?
|
| Global Health | 2 | 2014 | 382 | 0.270 |
Why?
|
| Lung Diseases | 1 | 2014 | 782 | 0.270 |
Why?
|
| Didanosine | 2 | 2006 | 13 | 0.270 |
Why?
|
| Osteosarcoma | 2 | 2015 | 73 | 0.260 |
Why?
|
| Testosterone | 3 | 2025 | 402 | 0.260 |
Why?
|
| Infant, Newborn | 11 | 2025 | 6158 | 0.260 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2008 | 140 | 0.260 |
Why?
|
| Memory, Short-Term | 3 | 2015 | 257 | 0.260 |
Why?
|
| Kidney Calculi | 1 | 2007 | 36 | 0.260 |
Why?
|
| Placebos | 8 | 2020 | 197 | 0.260 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 1370 | 0.250 |
Why?
|
| Animals | 25 | 2025 | 37243 | 0.250 |
Why?
|
| Piperazines | 2 | 2019 | 345 | 0.250 |
Why?
|
| Achievement | 3 | 2016 | 60 | 0.250 |
Why?
|
| Costs and Cost Analysis | 3 | 2023 | 223 | 0.250 |
Why?
|
| Drug Combinations | 3 | 2024 | 346 | 0.250 |
Why?
|
| Radiosurgery | 2 | 2021 | 389 | 0.250 |
Why?
|
| Underage Drinking | 2 | 2016 | 23 | 0.250 |
Why?
|
| Infant | 12 | 2025 | 9577 | 0.240 |
Why?
|
| Age Factors | 6 | 2021 | 3276 | 0.240 |
Why?
|
| Sarcoma | 2 | 2021 | 189 | 0.240 |
Why?
|
| Mental Disorders | 3 | 2025 | 1095 | 0.240 |
Why?
|
| Sensitivity and Specificity | 9 | 2016 | 1939 | 0.240 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2012 | 31 | 0.240 |
Why?
|
| Cyproterone Acetate | 1 | 2025 | 2 | 0.230 |
Why?
|
| Alopecia Areata | 1 | 2025 | 13 | 0.230 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 3 | 2018 | 182 | 0.230 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2024 | 856 | 0.230 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2023 | 1097 | 0.230 |
Why?
|
| Polymorphism, Genetic | 4 | 2016 | 624 | 0.230 |
Why?
|
| Benchmarking | 3 | 2024 | 187 | 0.230 |
Why?
|
| Anxiety | 4 | 2022 | 1070 | 0.230 |
Why?
|
| Fluorenes | 3 | 2020 | 45 | 0.230 |
Why?
|
| Carrageenan | 1 | 2024 | 8 | 0.230 |
Why?
|
| Gene Expression | 2 | 2009 | 1487 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2024 | 397 | 0.230 |
Why?
|
| Australia | 8 | 2022 | 307 | 0.230 |
Why?
|
| Cohort Studies | 12 | 2024 | 5744 | 0.230 |
Why?
|
| Recovery of Function | 2 | 2025 | 665 | 0.220 |
Why?
|
| Linear Models | 4 | 2016 | 855 | 0.220 |
Why?
|
| Hope | 1 | 2024 | 24 | 0.220 |
Why?
|
| Hematocrit | 2 | 2016 | 103 | 0.220 |
Why?
|
| Program Evaluation | 3 | 2022 | 917 | 0.220 |
Why?
|
| Cefadroxil | 1 | 2024 | 8 | 0.220 |
Why?
|
| Sex Attractants | 1 | 2024 | 3 | 0.220 |
Why?
|
| Cephalexin | 1 | 2024 | 11 | 0.210 |
Why?
|
| Surveys and Questionnaires | 9 | 2025 | 5884 | 0.210 |
Why?
|
| Hepatitis C, Chronic | 3 | 2019 | 146 | 0.210 |
Why?
|
| Case-Control Studies | 5 | 2024 | 3574 | 0.210 |
Why?
|
| Benzimidazoles | 3 | 2020 | 177 | 0.210 |
Why?
|
| Gestational Age | 4 | 2021 | 918 | 0.210 |
Why?
|
| Abdominal Neoplasms | 2 | 2015 | 38 | 0.210 |
Why?
|
| Point-of-Care Systems | 2 | 2023 | 184 | 0.210 |
Why?
|
| Macaca nemestrina | 1 | 2023 | 29 | 0.210 |
Why?
|
| Area Under Curve | 6 | 2019 | 319 | 0.210 |
Why?
|
| Craniosynostoses | 1 | 2024 | 57 | 0.200 |
Why?
|
| Spain | 3 | 2018 | 45 | 0.200 |
Why?
|
| Cranial Sutures | 1 | 2023 | 10 | 0.200 |
Why?
|
| Oxytocin | 1 | 2004 | 52 | 0.200 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2023 | 20 | 0.200 |
Why?
|
| Frontal Bone | 1 | 2023 | 21 | 0.200 |
Why?
|
| Drug Carriers | 1 | 2024 | 126 | 0.200 |
Why?
|
| South Australia | 2 | 2020 | 4 | 0.200 |
Why?
|
| Neoplasms | 3 | 2015 | 2687 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 374 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2013 | 2152 | 0.200 |
Why?
|
| Motivational Interviewing | 2 | 2022 | 115 | 0.200 |
Why?
|
| Quinolones | 1 | 2024 | 135 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2015 | 137 | 0.190 |
Why?
|
| Estradiol | 5 | 2025 | 525 | 0.190 |
Why?
|
| HIV Antibodies | 2 | 2021 | 61 | 0.190 |
Why?
|
| Olfactory Receptor Neurons | 2 | 2017 | 42 | 0.190 |
Why?
|
| Mental Health | 3 | 2024 | 742 | 0.190 |
Why?
|
| Survival Rate | 4 | 2015 | 1934 | 0.190 |
Why?
|
| Time Factors | 6 | 2025 | 6869 | 0.190 |
Why?
|
| Calibration | 2 | 2013 | 149 | 0.190 |
Why?
|
| Uganda | 4 | 2025 | 85 | 0.180 |
Why?
|
| Policy Making | 1 | 2022 | 97 | 0.180 |
Why?
|
| Cell Phone | 1 | 2022 | 76 | 0.180 |
Why?
|
| Tuberculosis | 1 | 2025 | 280 | 0.180 |
Why?
|
| Alcoholics | 1 | 2021 | 2 | 0.180 |
Why?
|
| Escherichia coli Infections | 2 | 2013 | 115 | 0.180 |
Why?
|
| Sex Workers | 1 | 2021 | 10 | 0.180 |
Why?
|
| Temperature | 2 | 2016 | 660 | 0.180 |
Why?
|
| Magnetic Phenomena | 1 | 2021 | 10 | 0.180 |
Why?
|
| Creatinine | 3 | 2018 | 485 | 0.180 |
Why?
|
| Cystic Fibrosis | 2 | 2022 | 1100 | 0.180 |
Why?
|
| Plasma | 3 | 2015 | 220 | 0.180 |
Why?
|
| Motor Skills Disorders | 1 | 2021 | 29 | 0.180 |
Why?
|
| Blood Platelets | 1 | 2025 | 427 | 0.180 |
Why?
|
| Depressive Disorder | 2 | 2021 | 391 | 0.180 |
Why?
|
| Feedback, Psychological | 1 | 2021 | 23 | 0.180 |
Why?
|
| Parental Leave | 1 | 2021 | 26 | 0.180 |
Why?
|
| New York City | 1 | 2021 | 89 | 0.180 |
Why?
|
| Heterosexuality | 1 | 2021 | 42 | 0.180 |
Why?
|
| Bariatric Surgery | 1 | 2025 | 217 | 0.180 |
Why?
|
| Ethambutol | 1 | 2021 | 25 | 0.180 |
Why?
|
| Sulfonamides | 3 | 2011 | 505 | 0.170 |
Why?
|
| Restaurants | 1 | 2021 | 25 | 0.170 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 2030 | 0.170 |
Why?
|
| Emergency Service, Hospital | 5 | 2025 | 2114 | 0.170 |
Why?
|
| Breast Feeding | 1 | 2025 | 434 | 0.170 |
Why?
|
| Haplotypes | 3 | 2012 | 497 | 0.170 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2022 | 100 | 0.170 |
Why?
|
| Schools | 4 | 2021 | 449 | 0.170 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2021 | 33 | 0.170 |
Why?
|
| Rifampin | 1 | 2021 | 84 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2015 | 3705 | 0.170 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 1355 | 0.170 |
Why?
|
| Urocanic Acid | 1 | 2020 | 1 | 0.170 |
Why?
|
| Vagina | 4 | 2025 | 193 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2021 | 83 | 0.170 |
Why?
|
| Semen | 1 | 2000 | 21 | 0.170 |
Why?
|
| Smell | 2 | 2021 | 122 | 0.170 |
Why?
|
| Incidence | 7 | 2024 | 2830 | 0.170 |
Why?
|
| Azithromycin | 1 | 2021 | 97 | 0.170 |
Why?
|
| Parents | 3 | 2021 | 1423 | 0.170 |
Why?
|
| Cytokines | 2 | 2008 | 2083 | 0.160 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2021 | 62 | 0.160 |
Why?
|
| Early Diagnosis | 3 | 2016 | 240 | 0.160 |
Why?
|
| Maxillofacial Development | 1 | 2020 | 20 | 0.160 |
Why?
|
| Poland | 2 | 2017 | 35 | 0.160 |
Why?
|
| Vaginal Creams, Foams, and Jellies | 1 | 2020 | 4 | 0.160 |
Why?
|
| Intimate Partner Violence | 1 | 2022 | 91 | 0.160 |
Why?
|
| Probenecid | 1 | 2019 | 8 | 0.160 |
Why?
|
| Models, Biological | 2 | 2018 | 1810 | 0.160 |
Why?
|
| Income | 1 | 2021 | 207 | 0.160 |
Why?
|
| Cluster Analysis | 3 | 2016 | 517 | 0.160 |
Why?
|
| Pandemics | 3 | 2023 | 1645 | 0.160 |
Why?
|
| Metronidazole | 1 | 2019 | 20 | 0.160 |
Why?
|
| Monitoring, Ambulatory | 1 | 2020 | 91 | 0.160 |
Why?
|
| Drug Utilization | 2 | 2017 | 169 | 0.150 |
Why?
|
| Drug Delivery Systems | 2 | 2023 | 359 | 0.150 |
Why?
|
| Qualitative Research | 2 | 2024 | 1448 | 0.150 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 2849 | 0.150 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 176 | 0.150 |
Why?
|
| Neutrophils | 1 | 2025 | 1274 | 0.150 |
Why?
|
| Directive Counseling | 2 | 2016 | 48 | 0.150 |
Why?
|
| Thailand | 3 | 2025 | 17 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2021 | 413 | 0.150 |
Why?
|
| Point-of-Care Testing | 1 | 2019 | 35 | 0.150 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 4316 | 0.150 |
Why?
|
| Contrast Media | 2 | 2015 | 463 | 0.150 |
Why?
|
| Mass Screening | 3 | 2023 | 1296 | 0.150 |
Why?
|
| Stavudine | 1 | 2018 | 8 | 0.150 |
Why?
|
| Social Class | 1 | 2021 | 278 | 0.150 |
Why?
|
| Executive Function | 1 | 2024 | 453 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 411 | 0.150 |
Why?
|
| Reference Values | 1 | 2020 | 801 | 0.150 |
Why?
|
| Therapeutic Equivalency | 1 | 2018 | 31 | 0.150 |
Why?
|
| Cryoprotective Agents | 1 | 2018 | 10 | 0.150 |
Why?
|
| Vitrification | 1 | 2018 | 6 | 0.150 |
Why?
|
| Renal Insufficiency | 2 | 2018 | 162 | 0.150 |
Why?
|
| Blood Vessels | 1 | 2020 | 180 | 0.150 |
Why?
|
| Liquid Phase Microextraction | 1 | 2018 | 2 | 0.150 |
Why?
|
| Blood Proteins | 1 | 2000 | 244 | 0.150 |
Why?
|
| Capsules | 1 | 2018 | 39 | 0.150 |
Why?
|
| Delayed-Action Preparations | 3 | 2025 | 178 | 0.140 |
Why?
|
| Cognition | 2 | 2025 | 1179 | 0.140 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2018 | 26 | 0.140 |
Why?
|
| Antibodies, Neutralizing | 1 | 2021 | 302 | 0.140 |
Why?
|
| Fiber Optic Technology | 1 | 1998 | 23 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 2283 | 0.140 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2018 | 41 | 0.140 |
Why?
|
| Pelvic Neoplasms | 2 | 2015 | 25 | 0.140 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 138 | 0.140 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2018 | 11 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2018 | 101 | 0.140 |
Why?
|
| Chemistry Techniques, Analytical | 1 | 2018 | 21 | 0.140 |
Why?
|
| Nanomedicine | 1 | 2018 | 45 | 0.140 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 325 | 0.140 |
Why?
|
| Administration, Intravaginal | 3 | 2025 | 17 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 609 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 1437 | 0.140 |
Why?
|
| Appendicitis | 1 | 2019 | 139 | 0.140 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1998 | 77 | 0.140 |
Why?
|
| Mucus | 1 | 1998 | 78 | 0.140 |
Why?
|
| Legislation, Drug | 1 | 2018 | 83 | 0.140 |
Why?
|
| Arthropod Antennae | 1 | 2017 | 2 | 0.140 |
Why?
|
| Carbamates | 2 | 2009 | 46 | 0.140 |
Why?
|
| Mucous Membrane | 1 | 2018 | 126 | 0.140 |
Why?
|
| ADAM Proteins | 1 | 2017 | 59 | 0.140 |
Why?
|
| Substrate Specificity | 1 | 2018 | 385 | 0.140 |
Why?
|
| Spine | 1 | 2019 | 179 | 0.130 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 268 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2018 | 104 | 0.130 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1949 | 0.130 |
Why?
|
| Kidney | 5 | 2016 | 1467 | 0.130 |
Why?
|
| Impulsive Behavior | 1 | 2019 | 152 | 0.130 |
Why?
|
| Genes, MDR | 1 | 2017 | 3 | 0.130 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2017 | 133 | 0.130 |
Why?
|
| Eosinophil Peroxidase | 1 | 2017 | 9 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 239 | 0.130 |
Why?
|
| Insect Proteins | 1 | 2017 | 38 | 0.130 |
Why?
|
| General Practice | 2 | 2014 | 30 | 0.130 |
Why?
|
| Gels | 2 | 2015 | 80 | 0.130 |
Why?
|
| Macaca mulatta | 3 | 2023 | 186 | 0.130 |
Why?
|
| Bone Diseases | 1 | 2017 | 64 | 0.130 |
Why?
|
| Bronchoscopy | 1 | 1998 | 225 | 0.130 |
Why?
|
| Clinical Studies as Topic | 1 | 2016 | 12 | 0.130 |
Why?
|
| Seroconversion | 3 | 2022 | 46 | 0.130 |
Why?
|
| Phosphorylation | 4 | 2015 | 1767 | 0.130 |
Why?
|
| Sweden | 1 | 2017 | 99 | 0.130 |
Why?
|
| Quality Control | 2 | 2015 | 173 | 0.130 |
Why?
|
| Inosine | 1 | 2016 | 14 | 0.130 |
Why?
|
| Enzymes | 1 | 2017 | 64 | 0.130 |
Why?
|
| Nocturia | 1 | 2016 | 9 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 143 | 0.130 |
Why?
|
| Absorptiometry, Photon | 4 | 2019 | 263 | 0.130 |
Why?
|
| Direct-to-Consumer Advertising | 1 | 2016 | 7 | 0.130 |
Why?
|
| Aptitude Tests | 1 | 2016 | 4 | 0.130 |
Why?
|
| Acute Disease | 1 | 2019 | 993 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2018 | 188 | 0.130 |
Why?
|
| Guanosine | 1 | 2016 | 41 | 0.130 |
Why?
|
| Peroxidase | 1 | 2017 | 182 | 0.130 |
Why?
|
| Blastocystis Infections | 1 | 1996 | 1 | 0.130 |
Why?
|
| Computer Simulation | 2 | 2021 | 995 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2025 | 1215 | 0.120 |
Why?
|
| Health Status | 2 | 2025 | 823 | 0.120 |
Why?
|
| Exercise | 2 | 2025 | 2086 | 0.120 |
Why?
|
| Reference Standards | 2 | 2020 | 184 | 0.120 |
Why?
|
| Intersectoral Collaboration | 1 | 2016 | 59 | 0.120 |
Why?
|
| Professional Role | 2 | 2015 | 168 | 0.120 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 7685 | 0.120 |
Why?
|
| Twist-Related Protein 1 | 2 | 2020 | 9 | 0.120 |
Why?
|
| Spermatozoa | 1 | 2016 | 96 | 0.120 |
Why?
|
| Biological Transport | 1 | 2017 | 403 | 0.120 |
Why?
|
| Purine-Nucleoside Phosphorylase | 2 | 2006 | 6 | 0.120 |
Why?
|
| Methanol | 1 | 2016 | 43 | 0.120 |
Why?
|
| Bisexuality | 1 | 2016 | 31 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2018 | 317 | 0.120 |
Why?
|
| Comorbidity | 4 | 2021 | 1657 | 0.120 |
Why?
|
| Prognosis | 2 | 2015 | 3995 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2016 | 70 | 0.120 |
Why?
|
| Cyclohexanes | 1 | 2015 | 21 | 0.120 |
Why?
|
| Solutions | 1 | 2016 | 168 | 0.120 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 121 | 0.120 |
Why?
|
| Population Dynamics | 1 | 2016 | 148 | 0.120 |
Why?
|
| Guidelines as Topic | 2 | 2017 | 272 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 296 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1996 | 128 | 0.110 |
Why?
|
| Health Promotion | 3 | 2022 | 750 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 1267 | 0.110 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 191 | 0.110 |
Why?
|
| Phenotype | 3 | 2019 | 3143 | 0.110 |
Why?
|
| Medication Reconciliation | 1 | 2015 | 30 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2016 | 355 | 0.110 |
Why?
|
| Urinary Tract Infections | 2 | 2017 | 193 | 0.110 |
Why?
|
| Blood | 1 | 2015 | 113 | 0.110 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2014 | 19 | 0.110 |
Why?
|
| Saliva | 1 | 2016 | 240 | 0.110 |
Why?
|
| Adenosine | 1 | 2016 | 241 | 0.110 |
Why?
|
| Maxillofacial Injuries | 1 | 2014 | 1 | 0.110 |
Why?
|
| Brain Damage, Chronic | 1 | 2014 | 18 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2017 | 636 | 0.110 |
Why?
|
| Intracellular Space | 1 | 2014 | 68 | 0.110 |
Why?
|
| Child Development | 2 | 2020 | 471 | 0.110 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 89 | 0.110 |
Why?
|
| Injections, Intramuscular | 2 | 2021 | 131 | 0.110 |
Why?
|
| Single-Blind Method | 3 | 2019 | 286 | 0.110 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2014 | 37 | 0.110 |
Why?
|
| Skull Fractures | 1 | 2014 | 38 | 0.110 |
Why?
|
| Triazoles | 1 | 2015 | 154 | 0.110 |
Why?
|
| Motivation | 2 | 2016 | 592 | 0.110 |
Why?
|
| Community Health Services | 1 | 2016 | 228 | 0.110 |
Why?
|
| Virulence Factors | 2 | 2013 | 160 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 1998 | 383 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2025 | 351 | 0.100 |
Why?
|
| Prevalence | 5 | 2021 | 2745 | 0.100 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 792 | 0.100 |
Why?
|
| Mortality | 1 | 2016 | 360 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2018 | 3466 | 0.100 |
Why?
|
| Eating | 1 | 2016 | 394 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2016 | 299 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 284 | 0.100 |
Why?
|
| Glycerophospholipids | 2 | 2023 | 34 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2019 | 1021 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 416 | 0.100 |
Why?
|
| Spironolactone | 2 | 2023 | 34 | 0.100 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 668 | 0.100 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 181 | 0.100 |
Why?
|
| Carrier State | 1 | 2013 | 70 | 0.100 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 349 | 0.100 |
Why?
|
| Administration, Topical | 2 | 2015 | 149 | 0.100 |
Why?
|
| Water | 1 | 2016 | 461 | 0.090 |
Why?
|
| Mutation | 5 | 2025 | 3984 | 0.090 |
Why?
|
| Premature Birth | 1 | 2016 | 343 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 323 | 0.090 |
Why?
|
| Victoria | 2 | 2023 | 18 | 0.090 |
Why?
|
| Uropathogenic Escherichia coli | 1 | 2011 | 4 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2017 | 790 | 0.090 |
Why?
|
| Histone Demethylases | 2 | 2023 | 31 | 0.090 |
Why?
|
| Organic Anion Transporters | 1 | 2011 | 11 | 0.090 |
Why?
|
| Cystitis | 1 | 2011 | 23 | 0.090 |
Why?
|
| Pravastatin | 1 | 2011 | 41 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 1068 | 0.090 |
Why?
|
| Proline | 1 | 2012 | 76 | 0.090 |
Why?
|
| Anion Exchange Resins | 1 | 2011 | 7 | 0.090 |
Why?
|
| Fibrosis | 1 | 2014 | 539 | 0.090 |
Why?
|
| Data Collection | 1 | 2014 | 660 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 766 | 0.090 |
Why?
|
| Decision Making | 1 | 2019 | 947 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2012 | 83 | 0.090 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2011 | 53 | 0.090 |
Why?
|
| Membrane Proteins | 1 | 2017 | 1149 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2013 | 283 | 0.090 |
Why?
|
| Metabolic Detoxication, Phase I | 1 | 2010 | 6 | 0.090 |
Why?
|
| Food-Drug Interactions | 1 | 2010 | 11 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1497 | 0.090 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 34 | 0.080 |
Why?
|
| Antacids | 1 | 2010 | 16 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2020 | 707 | 0.080 |
Why?
|
| Pyrrolidinones | 1 | 2010 | 30 | 0.080 |
Why?
|
| Students | 1 | 2016 | 627 | 0.080 |
Why?
|
| Smoking | 1 | 2018 | 1610 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2018 | 1985 | 0.080 |
Why?
|
| Phylogeny | 3 | 2024 | 1000 | 0.080 |
Why?
|
| Wounds and Injuries | 2 | 2016 | 834 | 0.080 |
Why?
|
| Infusions, Parenteral | 1 | 2010 | 43 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 247 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2015 | 633 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2014 | 511 | 0.080 |
Why?
|
| Osteogenesis | 2 | 2023 | 197 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2016 | 1103 | 0.080 |
Why?
|
| Adenoma | 1 | 2012 | 223 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2010 | 1311 | 0.080 |
Why?
|
| Memory Disorders | 1 | 2011 | 177 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2012 | 245 | 0.080 |
Why?
|
| Bluetongue | 1 | 2009 | 5 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2011 | 200 | 0.080 |
Why?
|
| Cattle Diseases | 1 | 2009 | 24 | 0.080 |
Why?
|
| Taxes | 1 | 2009 | 14 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2021 | 897 | 0.080 |
Why?
|
| Social Marketing | 1 | 2009 | 16 | 0.080 |
Why?
|
| Tablets | 2 | 2022 | 41 | 0.080 |
Why?
|
| Molecular Structure | 1 | 2010 | 498 | 0.080 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 523 | 0.080 |
Why?
|
| Information Services | 1 | 2009 | 48 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2024 | 805 | 0.070 |
Why?
|
| Germany | 2 | 2021 | 128 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2024 | 365 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2013 | 827 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 269 | 0.070 |
Why?
|
| Hypertension | 1 | 2017 | 1249 | 0.070 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2008 | 27 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 509 | 0.070 |
Why?
|
| Liver | 3 | 2013 | 1807 | 0.070 |
Why?
|
| Tracheal Diseases | 1 | 2008 | 15 | 0.070 |
Why?
|
| Hospitalization | 1 | 2018 | 2228 | 0.070 |
Why?
|
| Los Angeles | 2 | 2019 | 77 | 0.070 |
Why?
|
| Politics | 1 | 2009 | 101 | 0.070 |
Why?
|
| Cities | 2 | 2020 | 132 | 0.070 |
Why?
|
| Mice | 6 | 2024 | 17828 | 0.070 |
Why?
|
| Sleep | 1 | 2015 | 800 | 0.070 |
Why?
|
| Colorado | 1 | 2018 | 4543 | 0.070 |
Why?
|
| Demography | 2 | 2022 | 298 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 1047 | 0.070 |
Why?
|
| Research Design | 1 | 2014 | 1120 | 0.070 |
Why?
|
| Pheromones | 2 | 2024 | 26 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 69 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 2533 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1441 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 1522 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 448 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2009 | 280 | 0.070 |
Why?
|
| Kinetics | 1 | 2010 | 1649 | 0.070 |
Why?
|
| Brain | 1 | 2019 | 2791 | 0.070 |
Why?
|
| Receptors, Pheromone | 1 | 2006 | 3 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2015 | 1090 | 0.070 |
Why?
|
| Automobile Driving | 1 | 2009 | 150 | 0.070 |
Why?
|
| Binge Drinking | 2 | 2018 | 45 | 0.070 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 1076 | 0.060 |
Why?
|
| Animal Communication | 1 | 2006 | 18 | 0.060 |
Why?
|
| Gene Products, vpr | 1 | 2006 | 2 | 0.060 |
Why?
|
| Evidence-Based Practice | 1 | 2009 | 234 | 0.060 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 1 | 2006 | 12 | 0.060 |
Why?
|
| Pyrimidinones | 1 | 2007 | 114 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2006 | 38 | 0.060 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 253 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 195 | 0.060 |
Why?
|
| Adipocytes | 1 | 2008 | 227 | 0.060 |
Why?
|
| Esomeprazole | 1 | 2006 | 7 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 824 | 0.060 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 15 | 0.060 |
Why?
|
| School Health Services | 1 | 2009 | 231 | 0.060 |
Why?
|
| Pharmacology, Clinical | 1 | 2006 | 8 | 0.060 |
Why?
|
| Ribosomal Proteins | 1 | 2006 | 92 | 0.060 |
Why?
|
| Phosphatidylethanolamines | 1 | 2006 | 76 | 0.060 |
Why?
|
| Health Education | 1 | 2009 | 360 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 413 | 0.060 |
Why?
|
| Base Sequence | 2 | 2006 | 2176 | 0.060 |
Why?
|
| Risk Factors | 5 | 2019 | 10385 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3636 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1281 | 0.060 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2006 | 158 | 0.060 |
Why?
|
| Education | 1 | 2006 | 110 | 0.060 |
Why?
|
| Medical History Taking | 2 | 2016 | 117 | 0.060 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 108 | 0.060 |
Why?
|
| Drug Liberation | 1 | 2025 | 35 | 0.060 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 1321 | 0.060 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 667 | 0.060 |
Why?
|
| Northern Territory | 1 | 2024 | 3 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2024 | 29 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2009 | 2925 | 0.060 |
Why?
|
| Ghana | 1 | 2024 | 38 | 0.060 |
Why?
|
| Chitosan | 1 | 2025 | 34 | 0.060 |
Why?
|
| World Health Organization | 1 | 2005 | 125 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2023 | 3029 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2007 | 395 | 0.060 |
Why?
|
| Lymphopenia | 1 | 2004 | 66 | 0.060 |
Why?
|
| Urea | 1 | 2024 | 79 | 0.050 |
Why?
|
| Liposomes | 1 | 2006 | 218 | 0.050 |
Why?
|
| International Cooperation | 1 | 2005 | 202 | 0.050 |
Why?
|
| Polyesters | 1 | 2025 | 77 | 0.050 |
Why?
|
| Canada | 1 | 2025 | 408 | 0.050 |
Why?
|
| Deoxyadenosines | 1 | 2023 | 9 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1312 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2014 | 2241 | 0.050 |
Why?
|
| Mitochondrial Proteins | 1 | 2006 | 258 | 0.050 |
Why?
|
| Proviruses | 1 | 2023 | 16 | 0.050 |
Why?
|
| Drug Substitution | 1 | 2024 | 56 | 0.050 |
Why?
|
| Community Mental Health Services | 1 | 2004 | 86 | 0.050 |
Why?
|
| Accidents, Traffic | 2 | 2016 | 186 | 0.050 |
Why?
|
| Canrenone | 1 | 2023 | 1 | 0.050 |
Why?
|
| Logistic Models | 2 | 2019 | 2093 | 0.050 |
Why?
|
| Immunoassay | 1 | 2003 | 111 | 0.050 |
Why?
|
| Disclosure | 1 | 2023 | 112 | 0.050 |
Why?
|
| Cell Movement | 2 | 2017 | 969 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2015 | 204 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 105 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2006 | 401 | 0.050 |
Why?
|
| Rilpivirine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Body Weight | 2 | 2018 | 996 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 181 | 0.050 |
Why?
|
| Blood Cells | 1 | 2022 | 39 | 0.050 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2022 | 61 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 95 | 0.050 |
Why?
|
| Models, Statistical | 2 | 2017 | 665 | 0.050 |
Why?
|
| Benin | 1 | 2021 | 5 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 48 | 0.050 |
Why?
|
| Safe Sex | 1 | 2021 | 24 | 0.050 |
Why?
|
| Sex Work | 1 | 2021 | 22 | 0.040 |
Why?
|
| Pruritus | 1 | 2021 | 64 | 0.040 |
Why?
|
| Policy | 1 | 2023 | 149 | 0.040 |
Why?
|
| Trust | 1 | 2023 | 143 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 76 | 0.040 |
Why?
|
| Social Media | 1 | 2024 | 159 | 0.040 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2021 | 36 | 0.040 |
Why?
|
| Risk | 2 | 2021 | 913 | 0.040 |
Why?
|
| Switzerland | 1 | 2021 | 39 | 0.040 |
Why?
|
| Absenteeism | 1 | 2021 | 52 | 0.040 |
Why?
|
| Re-Irradiation | 1 | 2021 | 9 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 433 | 0.040 |
Why?
|
| Siblings | 1 | 2022 | 216 | 0.040 |
Why?
|
| Immunotoxins | 2 | 1991 | 55 | 0.040 |
Why?
|
| Crisis Intervention | 1 | 2021 | 33 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2021 | 149 | 0.040 |
Why?
|
| Feedback | 1 | 2021 | 174 | 0.040 |
Why?
|
| Feces | 2 | 2011 | 481 | 0.040 |
Why?
|
| Larva | 1 | 2021 | 234 | 0.040 |
Why?
|
| Glucuronides | 1 | 2000 | 19 | 0.040 |
Why?
|
| Mycobacterium avium Complex | 1 | 2021 | 87 | 0.040 |
Why?
|
| Wnt1 Protein | 1 | 2020 | 8 | 0.040 |
Why?
|
| Sperm Motility | 1 | 2020 | 33 | 0.040 |
Why?
|
| Hepacivirus | 1 | 2022 | 238 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2006 | 927 | 0.040 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2020 | 62 | 0.040 |
Why?
|
| Substance Abuse Detection | 1 | 2021 | 101 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2023 | 428 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 82 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 704 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 104 | 0.040 |
Why?
|
| Acyclovir | 1 | 2000 | 95 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2024 | 433 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 1999 | 13 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 378 | 0.040 |
Why?
|
| Bacteroides fragilis | 1 | 2019 | 12 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 116 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 85 | 0.040 |
Why?
|
| Action Potentials | 2 | 2017 | 485 | 0.040 |
Why?
|
| Radiation Injuries | 1 | 2021 | 147 | 0.040 |
Why?
|
| Herpes Simplex | 1 | 2000 | 95 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2022 | 336 | 0.040 |
Why?
|
| Health Surveys | 1 | 2021 | 520 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2024 | 387 | 0.040 |
Why?
|
| Embryonic Development | 1 | 2020 | 117 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2020 | 236 | 0.040 |
Why?
|
| North America | 1 | 2020 | 304 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2021 | 203 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 104 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2019 | 142 | 0.040 |
Why?
|
| Hip | 1 | 2019 | 57 | 0.040 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2019 | 39 | 0.040 |
Why?
|
| Cartilage | 1 | 2020 | 192 | 0.040 |
Why?
|
| Intestine, Large | 1 | 2018 | 14 | 0.040 |
Why?
|
| Lymphoid Tissue | 1 | 2019 | 79 | 0.040 |
Why?
|
| Cadherins | 1 | 2020 | 203 | 0.040 |
Why?
|
| Uridine Monophosphate | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 392 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2020 | 2480 | 0.040 |
Why?
|
| Oils | 1 | 2018 | 21 | 0.040 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2018 | 41 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 683 | 0.040 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2021 | 260 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 82 | 0.040 |
Why?
|
| Cervix Uteri | 1 | 2018 | 52 | 0.040 |
Why?
|
| Safety | 1 | 2020 | 348 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2018 | 128 | 0.040 |
Why?
|
| Program Development | 1 | 2020 | 362 | 0.040 |
Why?
|
| Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.030 |
Why?
|
| Solvents | 1 | 2018 | 112 | 0.030 |
Why?
|
| Furans | 2 | 2009 | 24 | 0.030 |
Why?
|
| Chondrocytes | 1 | 2020 | 226 | 0.030 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2017 | 1 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2021 | 301 | 0.030 |
Why?
|
| Histones | 1 | 2023 | 632 | 0.030 |
Why?
|
| Urinalysis | 1 | 2018 | 77 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 188 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2023 | 2497 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 550 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2018 | 124 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2017 | 21 | 0.030 |
Why?
|
| California | 1 | 2018 | 438 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2697 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2020 | 537 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2017 | 28 | 0.030 |
Why?
|
| Collagen Type IV | 1 | 2017 | 26 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 107 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2017 | 241 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2017 | 143 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1569 | 0.030 |
Why?
|
| Odorants | 1 | 2017 | 111 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2017 | 68 | 0.030 |
Why?
|
| Equipment Design | 1 | 2018 | 518 | 0.030 |
Why?
|
| Membrane Transport Proteins | 2 | 2008 | 154 | 0.030 |
Why?
|
| Defective Viruses | 1 | 2016 | 5 | 0.030 |
Why?
|
| USSR | 1 | 2016 | 3 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 171 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2017 | 139 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 176 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 109 | 0.030 |
Why?
|
| Hepatitis B, Chronic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 158 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2016 | 111 | 0.030 |
Why?
|
| District of Columbia | 1 | 2016 | 33 | 0.030 |
Why?
|
| San Francisco | 1 | 2016 | 58 | 0.030 |
Why?
|
| Drosophila | 1 | 2017 | 152 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2015 | 28 | 0.030 |
Why?
|
| Florida | 1 | 2016 | 113 | 0.030 |
Why?
|
| Syphilis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 1 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 915 | 0.030 |
Why?
|
| Vitamin D | 1 | 2018 | 399 | 0.030 |
Why?
|
| Population | 1 | 2015 | 33 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 350 | 0.030 |
Why?
|
| Gross Domestic Product | 1 | 2014 | 1 | 0.030 |
Why?
|
| Plant Preparations | 1 | 2015 | 38 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2015 | 88 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2016 | 61 | 0.030 |
Why?
|
| Filtration | 1 | 2015 | 70 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 501 | 0.030 |
Why?
|
| Reproductive Health | 1 | 2016 | 91 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 78 | 0.030 |
Why?
|
| Abdomen | 1 | 2015 | 135 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 105 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 273 | 0.030 |
Why?
|
| Diphtheria Toxin | 2 | 1991 | 65 | 0.030 |
Why?
|
| Pelvis | 1 | 2015 | 113 | 0.030 |
Why?
|
| Africa | 1 | 2015 | 118 | 0.030 |
Why?
|
| Nonprescription Drugs | 1 | 2015 | 64 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2879 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2015 | 211 | 0.030 |
Why?
|
| Facial Bones | 1 | 2014 | 30 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2015 | 270 | 0.030 |
Why?
|
| Forecasting | 1 | 2016 | 384 | 0.030 |
Why?
|
| Rats | 1 | 2023 | 5591 | 0.030 |
Why?
|
| Protein Binding | 1 | 2000 | 2233 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 79 | 0.030 |
Why?
|
| Albuminuria | 1 | 2015 | 185 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 1261 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 475 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 564 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 433 | 0.030 |
Why?
|
| Lipids | 1 | 2018 | 675 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 620 | 0.030 |
Why?
|
| Vitamins | 1 | 2015 | 188 | 0.030 |
Why?
|
| Prescription Drugs | 1 | 2015 | 112 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 304 | 0.030 |
Why?
|
| Adiposity | 1 | 2018 | 522 | 0.030 |
Why?
|
| Interleukin-2 | 2 | 1991 | 451 | 0.030 |
Why?
|
| Mitochondria | 1 | 1999 | 958 | 0.020 |
Why?
|
| Health Plan Implementation | 1 | 2014 | 145 | 0.020 |
Why?
|
| Sample Size | 1 | 2013 | 127 | 0.020 |
Why?
|
| Monocytes | 1 | 2015 | 573 | 0.020 |
Why?
|
| Reimbursement Mechanisms | 1 | 2013 | 83 | 0.020 |
Why?
|
| New South Wales | 1 | 2011 | 18 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1991 | 663 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 522 | 0.020 |
Why?
|
| Inservice Training | 1 | 2013 | 122 | 0.020 |
Why?
|
| Darunavir | 1 | 2011 | 19 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2012 | 131 | 0.020 |
Why?
|
| Vinblastine | 1 | 2011 | 71 | 0.020 |
Why?
|
| Proteins | 1 | 2018 | 1009 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 43 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2017 | 1002 | 0.020 |
Why?
|
| Recurrence | 1 | 2015 | 1085 | 0.020 |
Why?
|
| Urine | 1 | 2011 | 62 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2011 | 98 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 993 | 0.020 |
Why?
|
| Physician Assistants | 1 | 2013 | 95 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 280 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 255 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 139 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 137 | 0.020 |
Why?
|
| Thiotepa | 1 | 2010 | 20 | 0.020 |
Why?
|
| Camptothecin | 1 | 2011 | 122 | 0.020 |
Why?
|
| Computer-Assisted Instruction | 1 | 2011 | 68 | 0.020 |
Why?
|
| Carmustine | 1 | 2010 | 53 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2013 | 137 | 0.020 |
Why?
|
| Transsexualism | 1 | 2010 | 20 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2015 | 559 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2015 | 718 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2015 | 575 | 0.020 |
Why?
|
| Candida | 1 | 2010 | 41 | 0.020 |
Why?
|
| Carboplatin | 1 | 2010 | 146 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2014 | 581 | 0.020 |
Why?
|
| Nausea | 1 | 2010 | 111 | 0.020 |
Why?
|
| Interferons | 1 | 2011 | 195 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 3397 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2390 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 205 | 0.020 |
Why?
|
| Cholesterol | 1 | 2011 | 403 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 644 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2010 | 276 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2015 | 766 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 2011 | 199 | 0.020 |
Why?
|
| Athletic Injuries | 1 | 2016 | 515 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 513 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 77 | 0.020 |
Why?
|
| Disease Progression | 1 | 2017 | 2752 | 0.020 |
Why?
|
| Prodrugs | 1 | 2009 | 46 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 397 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 309 | 0.020 |
Why?
|
| Serum | 1 | 2007 | 60 | 0.020 |
Why?
|
| Point Mutation | 1 | 2008 | 238 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 848 | 0.020 |
Why?
|
| Cattle | 1 | 2009 | 990 | 0.020 |
Why?
|
| Fatty Alcohols | 1 | 2006 | 6 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2010 | 787 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 85 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 898 | 0.020 |
Why?
|
| Electric Conductivity | 1 | 2006 | 86 | 0.020 |
Why?
|
| vpr Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 2 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2008 | 501 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2020 | 5092 | 0.020 |
Why?
|
| Calorimetry | 1 | 2006 | 71 | 0.020 |
Why?
|
| Quebec | 1 | 2006 | 10 | 0.020 |
Why?
|
| Ion Exchange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2007 | 325 | 0.020 |
Why?
|
| Chemical Fractionation | 1 | 2006 | 29 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 814 | 0.020 |
Why?
|
| Software | 1 | 2011 | 670 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 411 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 581 | 0.010 |
Why?
|
| Internationality | 1 | 2006 | 158 | 0.010 |
Why?
|
| Algorithms | 2 | 2004 | 1730 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2012 | 1149 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 850 | 0.010 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 239 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 890 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 4182 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2006 | 645 | 0.010 |
Why?
|
| Shiga Toxins | 2 | 1991 | 3 | 0.010 |
Why?
|
| Apoptosis | 1 | 2010 | 2551 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2171 | 0.010 |
Why?
|
| Bacterial Toxins | 2 | 1991 | 104 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 2362 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2000 | 201 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 1285 | 0.010 |
Why?
|
| Protein Engineering | 1 | 1990 | 107 | 0.000 |
Why?
|